• Japanese
  • Korean
  • Chinese
Cover Image

Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities

Executive Summary

Anti-Smoking Legislation Vital for Nicotine Addiction to go up in Smoke, says Report

Anti-smoking legislation and structured support from healthcare providers is essential to achieve widespread smoking cessation, claims a new report by healthcare experts GBI Research.

The new report* argues that the effectiveness of current pharmaceutical treatments depends as much on enforced legislation, such as smoking bans, and support from healthcare providers as an individual's willingness to quit.

According to the World Health Organization (WHO), up to half of all 'lifelong' tobacco users will die from a tobacco-related disease, while the five million deaths that occur as a result of smoking every year outnumber the collective lives lost to HIV/AIDS, malaria and tuberculosis. Nicotine addiction therefore represents a serious public health risk and must be met with effective cessation therapies.

GBI Research claims that the prevalent population for nicotine addiction stood at 136.7 million in 2011, while the 'diagnosed' population, defined as those going to visit a physician concerning smoking cessation, was only 40 million. Furthermore, GlaxoSmithKline claims that while 70% of smokers want to quit less than 5% actually do, indicating a massive opportunity for companies willing to enter the market.

Popular Nicotine Replacement Therapies (NRTs) are conveniently available over-the-counter and account for 75% of all smoking cessation therapies sold worldwide, with patches, gum, lozenges, sprays and inhalers available to deliver doses of nicotine and reduce the effects of withdrawal.

FDA-approved prescription medications for smoking cessation include the nicotine receptor agonist Chantix (varenicline) and the antidepressant Buproprion (marketed as Zyban, Wellbutrin, Voxra, Budeprion, and Aplenzin). However, while these drugs act to alleviate nicotine withdrawal symptoms and the severity of nicotine cravings, both carry associated risks of suicidal tendencies, with Chantix having been forced to carry a 'black box' warning since 2008.

The increasing emergence of smokeless electronic 'e-cigarette' products have split opinion as effective treatments as, while e-cigarettes are often marketed as anti-smoking treatments, they are often sponsored by large tobacco companies and arguably serve to keep smokers addicted. Furthermore, the 'e-cigarette' market is currently unregulated, while low-grade nicotine is often used, which may have unpleasant and possibly dangerous side-effects.

The report states that increasing numbers of patients seeking treatment are being supported by healthcare campaigns around the world. Government efforts are evident in the UK, where the NHS Stop Smoking service enabled over half a million patients to access smoking cessation therapy during April 2011-December 2011 alone.

The report goes on to indicate that future revenues will be made from smoking cessation therapies in countries where legislation and healthcare campaigns are not yet present. South East Asia represents a huge potential market for the next 15 years, as a very high smoking prevalence rate is contrasted with the lack of an established market for NRT or anti-smoking products. GBI Research healthcare analyst, Amy Baker, said: "This market is as yet largely untapped because of cultural attitudes to smoking and a lack of public health efforts; but, should any companies in the future crack the Asian markets, it will offer a massive opportunity."

The global nicotine addiction therapeutics market was estimated at $4.5 billion in 2011, indicating a CAGR of 3.1% between 2004 and 2011. The value is expected to reach $6.2 billion in 2018, following growth at a CAGR of 4.5% between 2011 and 2018.

Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities

The report provides insights into the substance abuse therapeutics market, including market forecasts up to 2018, and an in-depth analysis of the major substance abuse indications, which include nicotine addiction, alcohol dependence and opioid and cocaine abuse. It additionally gives insights into the substance abuse therapeutics R&D pipeline, and analyzes the competitive landscape through the analysis of M&A and licensing deals.

The report is built using data and information sourced from proprietary databases, primary and secondary secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Abstract

Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities

Summary

GBI Research, leading business intelligence provider has released its latest research report, entitled "Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities". The report provides insights into the substance abuse therapeutics market including market forecasts up to 2018. It provides an in-depth analysis of the major substance abuse indications, which include nicotine addiction, alcohol dependence and opioid and cocaine abuse, as well as insights into the substance abuse therapeutics R&D pipeline. In addition, it analyzes the competitive landscape through the analysis of M&A and licensing deals.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research finds that the substance abuse therapeutics market in the top seven markets was valued at $8.8 billion in 2011, increasing at a CAGR of 4.9% during the review period 2004-2011. The market is projected to witness moderate growth of 5.3% during the 2011-2018 forecast period to reach $12.7 billion. The moderate growth of the market can be attributed to the presence of generics in the market, low compliance with therapy due to the nature of addiction and the lack of innovative products in the pipeline. However, indications such as cocaine addiction, which currently have no approved products, are expected to see entries to the market and high-priced products such as Champix for smoking cessation will not see patent expiry in the forecast period.

Scope

  • Data and analysis on the substance abuse therapeutics market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the substance abuse therapeutics market from 2004-2011 with forecasts to 2018.
  • Market data on the therapeutic landscape, which covers nicotine addiction, alcohol dependence and opioid and cocaine abuse. This includes market size, annual cost of therapy, treatment flow algorithm.
  • Key drivers and restraints that have had a significant impact on the market and on each indication.
  • The competitive landscape of the global substance abuse therapeutics market, which includes companies such as Pfizer, GSK, Forest Laboratories, Alkermes and Reckitt Benckiser.
  • Key M&A activities and licensing agreements that took place from 2007 to 2011 in the global substance abuse therapeutics market.

Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the potential region and substance abuse therapeutics market segments poised for strong growth.
  • Create a more tailored country strategy through the understanding of key drivers and barriers of the global substance abuse therapeutics market.
  • Develop key strategic initiatives by understanding the key focus areas and top selling therapeutics of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

TOC

1 Table of Contents

1 Table of Contents 5

  • 1.1 List of Tables 8
  • 1.2 List of Figures 10

2 Substance Abuse Therapeutics Market to 2018 - Introduction 12

  • 2.1 Overview 12

3 Substance Abuse Therapeutics Market to 2018 - Market Overview 14

  • 3.1 Introduction 14
  • 3.2 Revenue Forecasts for Substance Abuse Therapeutics Market 14
    • 3.2.1 Revenue 14
    • 3.2.2 Annual Cost of Treatment 16
  • 3.3 Treatment Usage Patterns 17
    • 3.3.1 Diseased Population 17
    • 3.3.2 Diagnosed Population 18
    • 3.3.3 Prescription Population 19
  • 3.4 Drivers and Barriers for Substance Abuse Therapeutics Market 20
    • 3.4.1 Drivers 20
    • 3.4.2 Barriers 21

4 Substance Abuse Therapeutics Market to 2018 - Geographical Landscape 22

  • 4.1 The US 22
    • 4.1.1 Revenue 22
    • 4.1.2 Annual Cost of Treatment 23
    • 4.1.3 Treatment Usage Patterns 24
    • 4.1.4 Diagnosed Population 25
    • 4.1.5 Prescription Population 26
  • 4.2 Top Five Countries of Europe 27
    • 4.2.1 Revenue 27
    • 4.2.2 Annual Cost of Treatment 28
    • 4.2.3 Treatment Usage Patterns 29
  • 4.3 Japan 32
    • 4.3.1 Revenue 32
    • 4.3.2 Annual Cost of Treatment 34
    • 4.3.3 Treatment Usage Patterns 35

5 Substance Abuse Therapeutics Market to 2018 - Nicotine Addiction Therapeutics Market 38

  • 5.1 Introduction 38
    • 5.1.1 Treatment Flow Algorithm 39
    • 5.1.2 Opportunities/Unmet Needs 39
    • 5.1.3 Revenue 40
    • 5.1.4 Annual Cost of Treatment 42
    • 5.1.5 Treatment Usage Patterns 43
    • 5.1.6 Drivers and Barriers for the Nicotine Addiction Market 46
    • 5.1.7 Drivers 46
    • 5.1.8 Barriers 47
  • 5.2 Marketed Products 48
    • 5.2.1 Chantix (varenicline) 48
    • 5.2.2 Zyban (buproprion hydrochloride) 48
    • 5.2.3 Nicotine Replacement Therapies 48

6 Substance Abuse Therapeutics Market to 2018 - Alcohol Dependence Therapeutics Market 50

  • 6.1 Introduction 50
    • 6.1.1 Treatment Flow 51
    • 6.1.2 Opportunities/Unmet Needs 52
    • 6.1.3 Revenue 52
    • 6.1.4 Annual Cost of Treatment 54
    • 6.1.5 Treatment Usage Patterns 55
  • 6.2 Drivers and Barriers for Alcohol Dependence Therapeutic Market 58
    • 6.2.1 Drivers 58
    • 6.2.2 Barriers 59
  • 6.3 Marketed Products 59
    • 6.3.1 Detoxification treatment options 59
    • 6.3.2 Campral (acamprosate calcium) 59
    • 6.3.3 Antabuse (disulfurum) 60
    • 6.3.4 Vivitrol (naltrexone) 60

7 Substance Abuse Therapeutics Market to 2018 - Drug Abuse Therapeutics Market 61

  • 7.1 Introduction 61
    • 7.1.1 Opioid Abuse 61
    • 7.1.2 Cocaine Abuse 62
    • 7.1.3 Treatment Flow Algorithm 62
    • 7.1.4 Opportunities/Unmet Needs 63
  • 7.2 Revenues 63
    • 7.2.1 Annual Cost of Therapy 65
    • 7.2.2 Treatment Usage Patterns 66
  • 7.3 Drivers and Barriers for Drug Abuse 69
    • 7.3.1 Drivers 69
    • 7.3.2 Barriers 69
  • 7.4 Marketed Drugs - Opioid Abuse 70
    • 7.4.1 Methadone 70
    • 7.4.2 Suboxone (buprenorphine and naloxone) 70
    • 7.4.3 Buprenorphine Hydrochloride 70
    • 7.4.4 Vivitrol (naltrexone) 70
  • 7.5 Marketed Products - Cocaine Abuse 70
    • 7.5.1 Overview 70
    • 7.5.2 Sabril (vigabatrin) 70
    • 7.5.3 Fluoxetine 71
    • 7.5.4 Disulfiram (Antabuse) 71
    • 7.5.5 Naltrexone 71
    • 7.5.6 Topiramate 71
    • 7.5.7 Amantadine 71
    • 7.5.8 Baclofen 71
    • 7.5.9 Modafinil 71

8 Substance Abuse Therapeutics Market to 2018 - Product Pipeline Analysis 72

  • 8.1 R&D Pipeline - Nicotine Addiction Therapeutics Market 72
    • 8.1.1 Pre-clinical and Discovery Phase 72
    • 8.1.2 Phase I 72
    • 8.1.3 Phase II 72
    • 8.1.4 Promising Pipeline Molecules 72
  • 8.2 R&D Pipeline - Alcohol Dependence Therapeutics Market 73
    • 8.2.1 Pre-clinical and Discovery Phase 73
    • 8.2.2 Phase I 73
    • 8.2.3 Phase II 73
    • 8.2.4 NDA Filed 73
    • 8.2.5 Promising Molecules in the Pipeline 74
    • 8.2.6 NS11 74
  • 8.3 R&D Pipeline - Drug Abuse Therapeutics Market 75
    • 8.3.1 Pre-clinical and Discovery Phase 75
    • 8.3.2 Phase I 75
    • 8.3.3 Phase II 75
    • 8.3.4 Phase III 75
    • 8.3.5 Promising Molecules in the Pipeline 76

9 Substance Abuse Therapeutics Market to 2018 - Competitive Landscape 77

  • 9.1 GlaxoSmithKline 77
    • 9.1.1 Overview 77
    • 9.1.2 Major Products in the Substance Abuse Therapeutics Market 77
    • 9.1.3 SWOT Analysis 78
  • 9.2 Pfizer 78
    • 9.2.1 Overview 78
    • 9.2.2 Major Products in the Substance Abuse Therapeutics Market 78
    • 9.2.3 SWOT Analysis 79
  • 9.3 Alkermes 80
    • 9.3.1 Overview 80
    • 9.3.2 Major Products in the Substance Abuse Therapeutics Market 80
    • 9.3.3 SWOT Analysis 80
  • 9.4 Forest Laboratories, Inc. 81
    • 9.4.1 Overview 81
    • 9.4.2 Major Products in the Substance Abuse Therapeutics Market 81
    • 9.4.3 SWOT Analysis 81
  • 9.5 Teva Pharmaceuticals 82
    • 9.5.1 Overview 82
    • 9.5.2 Major Products in the Substance Abuse Therapeutics Market 82
    • 9.5.3 SWOT Analysis 82
  • 9.6 Reckitt Benckiser Pharmaceuticals 83
    • 9.6.1 Overview 83
    • 9.6.2 Major Products in the Substance Abuse Therapeutics Market 83
    • 9.6.3 SWOT Analysis 84

10 Substance Abuse Therapeutics Market to 2018 - Strategic Consolidations 85

  • 10.1 Mergers and Acquisitions (M&A) 85
    • 10.1.1 Deals by Year 85
    • 10.1.2 Deals by Geography 86
    • 10.1.3 Major Mergers and Acquisitions, 2007-2012 86
  • 10.2 Licensing Agreements 87
    • 10.2.1 Deals by Year 87
    • 10.2.2 Deals by Geography 88
    • 10.2.3 Major Licensing and Co-Development Agreements, 2007-2012 88

11 Substance Abuse Therapeutics Market to 2018 - Appendix 90

  • 11.1 Market Definitions 90
  • 11.2 Abbreviations 90
  • 11.3 Bibliography 91
  • 11.4 Research Methodology 93
    • 11.4.1 Coverage 93
    • 11.4.2 Secondary Research 93
    • 11.4.3 Primary Research 93
  • 11.5 Therapeutic Landscape 94
    • 11.5.1 Epidemiology-based Forecasting 94
    • 11.5.2 Market Size by Geography 96
  • 11.6 Geographical Landscape 97
  • 11.7 Pipeline Analysis 97
  • 11.8 Competitive Landscape 97
    • 11.8.1 Expert Panel Validation 97
  • 11.9 Contact Us 97
  • 11.10 Disclaimer 97

List of Tables

1.1 List of Tables

  • Table 1: Substance Abuse Therapeutics Market, Global, Revenue ($bn), 2004-2011 15
  • Table 2: Substance Abuse Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018 15
  • Table 3: Substance Abuse Therapeutics Market, Global, ACT ($), 2004-2011 16
  • Table 4: Substance Abuse Therapeutics Market, Global, ACT ($), 2011-2018 16
  • Table 5: Substance Abuse Therapeutics Market, Global, Diseased Population (Millions), 2004-2011 17
  • Table 6: Substance Abuse Therapeutics Market, Global, Diseased Population (Millions), 2011-2018 17
  • Table 7: Substance Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011 18
  • Table 8: Substance Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018 18
  • Table 9: Substance Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2011 19
  • Table 10: Substance Abuse Therapeutics Market, Global, Prescription Population (millions), 2011-2018 19
  • Table 11: Substance Abuse Therapeutics Market, The US, Revenue ($bn), 2004-2011 22
  • Table 12: Substance Abuse Therapeutics Market, The US, Revenue Forecasts ($bn), 2011-2018 22
  • Table 13: Substance Abuse Therapeutics Market, The US, ACT ($), 2004-2011 23
  • Table 14: Substance Abuse Therapeutics Market, The US, ACT ($), 2011-2018 23
  • Table 15: Substance Abuse Therapeutics Market, The US, Diseased Population (millions), 2004-2011 24
  • Table 16: Substance Abuse Therapeutics Market, The US, Diseased Population (millions), 2011-2018 24
  • Table 17: Substance Abuse Therapeutics Market, The US, Diagnosed Population (millions), 2004-2011 25
  • Table 18: Substance Abuse Therapeutics Market, The US, Diagnosed Population (millions), 2011-2018 25
  • Table 19: Substance Abuse Therapeutics Market, The US, Prescription Population (millions), 2004-2011 26
  • Table 20: Substance Abuse Therapeutics Market, The US, Prescription Population (millions), 2011-2018 26
  • Table 21: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2004-2011 27
  • Table 22: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2011-2018 27
  • Table 23: Substance Abuse Therapeutics Market, Top Five Countries of Europe, ACT ($), 2004-2011 28
  • Table 24: Substance Abuse Therapeutics Market, Top Five Countries of Europe, ACT ($), 2011-2018 28
  • Table 25: Substance Abuse Therapeutics Market, Top Five Countries of Europe Diseased Population (millions), 2004-2011 29
  • Table 26: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diseased Population (millions), 2011-2018 29
  • Table 27: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diagnosed Population (millions), 2004-2011 30
  • Table 28: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diagnosed Population (millions), 2011-2018 31
  • Table 29: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Prescription Population (millions), 2004-2011 31
  • Table 30: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Prescription Population (millions), 2011-2018 32
  • Table 31: Substance Abuse Therapeutics Market, Japan, Revenue ($m), 2004-2011 32
  • Table 32: Substance Abuse Therapeutics Market, Japan, Revenue Forecasts ($m), 2011-2018 33
  • Table 33: Substance Abuse Therapeutics Market, Japan, ACT ($), 2004-2011 34
  • Table 34: Substance Abuse Therapeutics Market, Japan, ACT ($), 2011-2018 34
  • Table 35: Substance Abuse Therapeutics Market, Japan, Diseased Population (millions), 2004-2011 35
  • Table 36: Substance Abuse Therapeutics Market, Japan, Diseased Population (millions, 2011-2018 35
  • Table 37: Substance Abuse Therapeutics Market, Japan, Diagnosed Population (millions), 2004-2011 36
  • Table 38: Substance Abuse Therapeutics Market, Japan, Diagnosed Population (millions), 2011-2018 36
  • Table 39: Substance Abuse Therapeutics Market, Japan, Prescription Population (millions), 2004-2011 37
  • Table 40: Substance Abuse Therapeutics Market, Japan, Prescription Population (millions), 2011-2018 37
  • Table 41: Nicotine Addiction Therapeutics Market, Global, Revenue ($bn), 2004-2011 40
  • Table 42: Nicotine Addiction Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018 40
  • Table 43: Nicotine Addiction Therapeutics Market, Global, ACT ($), 2004-2011 42
  • Table 44: Nicotine Addiction Therapeutics Market, Global, ACT ($), 2011-2018 42
  • Table 45: Nicotine Addiction Market, Global, Diseased Population (millions), 2004-2011 43
  • Table 46: Nicotine Addiction Therapeutics Market, Global, Diseased Population (millions), 2011-2018 43
  • Table 47: Nicotine Addiction Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011 44
  • Table 48: Nicotine Addiction Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018 44
  • Table 49: Nicotine Addiction Therapeutics Market, Global, Prescription Population (millions), 2004-2011 45
  • Table 50: Nicotine Addiction Therapeutics Market, Global, Prescription Population (millions), 2011-2018 45
  • Table 51: Alcohol Dependence Therapeutics Market, Global, Revenue ($m), 2004-2011 53
  • Table 52: Alcohol Dependence Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018 53
  • Table 53: Alcohol Dependence Therapeutics Market, Global, ACT ($), 2004-2011 54
  • Table 54: Alcohol Dependence Therapeutics Market, Global, ACT ($), 2011-2018 54
  • Table 55: Alcohol Dependence Therapeutic Market, Global, Diseased Population (millions), 2004-2011 55
  • Table 56: Alcohol Dependence Therapeutic Market, Global, Diseased Population (millions), 2011-2018 55
  • Table 57: Alcohol Dependence Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011 56
  • Table 58: Alcohol Dependence Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018 56
  • Table 59: Alcohol Dependence Therapeutics Market, Global, Prescription Population (000'), 2004-2011 57
  • Table 60: Alcohol Dependence Therapeutics Market, Global, Prescription Population (000'), 2011-2018 57
  • Table 61: Drug Abuse Therapeutics Market, Global, Revenue ($bn), 2004-2011 64
  • Table 62: Drug Abuse Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018 64
  • Table 63: Drug Abuse Therapeutics Market, Global, Average ACT ($), 2004-2011 65
  • Table 64: Drug Abuse Therapeutics Market, Global, Average ACT ($), 2011-2018 65
  • Table 65: Drug Abuse Therapeutics Market, Global, Diseased Population (millions), 2004-2011 66
  • Table 66: Drug Abuse Therapeutics Market, Global, Diseased Population (millions), 2011-2018 66
  • Table 67: Drug Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2011 67
  • Table 68: Drug Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2011-2018 67
  • Table 69: Drug Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2011 68
  • Table 70: Drug Abuse Therapeutics Market, Global, Prescription Population (millions), 2011-2018 68
  • Table 71: Nicotine Addiction Therapeutics Market, Global, R&D Pipeline in Pre-clinical and Discovery Phase, 2011 72
  • Table 72: Nicotine Addiction Therapeutics Market, Global, R&D Pipeline in Phase I, 2011 72
  • Table 73: Nicotine Addiction Therapeutics Market, Global, R&D Pipeline in Phase II, 2011 72
  • Table 74: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in Pre-clinical and Discovery Phase, 2011 73
  • Table 75: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in Phase I, 2011 73
  • Table 76: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in Phase II, 2011 73
  • Table 77: Alcohol Dependence Therapeutics Market, Global, R&D Pipeline in NDA Filed, 2011 73
  • Table 78: Drug Abuse Therapeutics Market, Global, Pre-clinical, 2011 75
  • Table 79: Drug Abuse Therapeutics Market, Global, Phase I, 2011 75
  • Table 80: Drug Abuse Therapeutics Market, Global, Phase II, 2011 75
  • Table 81: Drug Abuse Therapeutics Market, Global, Phase III, 2011 75

List of Figures

1.2 List of Figures

  • Figure 1: Substance Abuse Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 14
  • Figure 2: Substance Abuse Therapeutics Market, Global, ACT ($), 2004-2018 16
  • Figure 3: Substance Abuse Therapeutics Market, Global, Diseased Population (Millions), 2004-2018 17
  • Figure 4: Substance Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018 18
  • Figure 5: Substance Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2018 19
  • Figure 6: Substance Abuse Therapeutics Market, Drivers and Barriers, 2011 20
  • Figure 7: Substance Abuse Therapeutics Market, The US, Revenue Forecasts ($bn), 2004-2018 22
  • Figure 8: Substance Abuse Therapeutics Market, The US, ACT ($), 2004-2018 23
  • Figure 9: Substance Abuse Therapeutics Market, The US, Diseased Population (millions), 2004-2018 24
  • Figure 10: Substance Abuse Therapeutics Market, The US, Diagnosed Population (millions), 2004-2018 25
  • Figure 11: Substance Abuse Therapeutics Market, The US, Prescription Population (millions), 2004-2018 26
  • Figure 12: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2004-2018 27
  • Figure 13: Substance Abuse Therapeutics Market, Top Five Countries of Europe, ACT ($), 2004-2018 28
  • Figure 14: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diseased Population (millions), 2004-2018 29
  • Figure 15: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Diagnosed Population (millions), 2004-2018 30
  • Figure 16: Substance Abuse Therapeutics Market, Top Five Countries of Europe, Prescription Population (millions), 2004-2018 31
  • Figure 17: Substance Abuse Therapeutics Market, Japan, Revenue Forecasts ($m), 2004-2018 32
  • Figure 18: Substance Abuse Therapeutics Market, Japan, ACT ($), 2004-2018 34
  • Figure 19: Substance Abuse Therapeutics Market, Japan, Diseased Population (millions), 2004-2018 35
  • Figure 20: Substance Abuse Therapeutics Market, Japan, Diagnosed Population (millions), 2004-2018 36
  • Figure 21: Substance Abuse Therapeutics Market, Japan, Prescription Population (millions), 2004-2018 37
  • Figure 22: Nicotine Addiction Therapeutics Market, Treatment Flow Algorithm 39
  • Figure 23: Nicotine Addiction Therapeutics Market, Global, Revenue Forecasts ($bn), 2004-2018 40
  • Figure 24: Nicotine Addiction Therapeutics Market, Global, ACT ($), 2004-2018 42
  • Figure 25: Nicotine Addiction Therapeutics Market, Global, Diseased Population (millions), 2004-2018 43
  • Figure 26: Nicotine Addiction Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018 44
  • Figure 27: Nicotine Addiction Therapeutics Market, Global, Prescription Population (millions), 2004-2018 45
  • Figure 28: Nicotine Addiction Therapeutics Market, Global, Drivers and Barriers, 2011 46
  • Figure 29: Alcohol Dependence Therapeutics Market, Treatment Flow Algorithm 51
  • Figure 30: Alcohol Dependence Therapeutics Market, Global, Revenue Forecasts ($m), 2004-2018 52
  • Figure 31: Alcohol Dependence Therapeutics Market, Global, ACT ($), 2004-2018 54
  • Figure 32: Alcohol Dependence Therapeutics Market, Global, Diseased Population (millions), 2004-2018 55
  • Figure 33: Alcohol Dependence Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018 56
  • Figure 34: Alcohol Dependence Therapeutics Market, Global, Prescription Population (000'), 2004-2018 57
  • Figure 35: Alcohol Dependence Therapeutics Market, Global, Drivers and Barriers, 2011 58
  • Figure 36: Drug Abuse Therapeutics Market, Treatment Flow Algorithm 62
  • Figure 37: Drug Abuse Therapeutics Market, Global, Revenue ($bn), 2004-2018 63
  • Figure 38: Drug Abuse Therapeutics Market, Global, ACT ($), 2004-2018 65
  • Figure 39: Drug Abuse Therapeutics Market, Global, Diseased Population (millions), 2004-2018 66
  • Figure 40: Drug Abuse Therapeutics Market, Global, Diagnosed Population (millions), 2004-2018 67
  • Figure 41: Drug Abuse Therapeutics Market, Global, Prescription Population (millions), 2004-2018 68
  • Figure 42: Drug Abuse Therapeutics Market, Global, Drivers and Barriers, 2011 69
  • Figure 43: Substance Abuse Therapeutics Market, SWOT Analysis, GSK, 2011 78
  • Figure 44: Substance Abuse Therapeutics Market, SWOT Analysis, Pfizer, 2011 79
  • Figure 45: Substance Abuse Therapeutics Market, SWOT Analysis, Alkermes, 2011 80
  • Figure 46: Substance Abuse Therapeutics Market, SWOT Analysis, Forest Laboratories Inc., 2011 81
  • Figure 47: Substance Abuse Therapeutics Market, SWOT Analysis, Teva Pharmaceutical, 2011 82
  • Figure 48: Substance Abuse Therapeutics Market, SWOT Analysis, Reckitt Benckiser, 2011 84
  • Figure 49: Substance Abuse Therapeutics Market, Global, Major M&A Deals By Year, 2007-2012 85
  • Figure 50: Substance Abuse Therapeutics Market, Global, Major M&A Deals By Geography, 2007-2012 86
  • Figure 51: Substance Abuse Therapeutics Market, Global, R&D Licensing Deals By Year, 2007-2012 87
  • Figure 52: Substance Abuse Therapeutics Market, Global, Major R&D Licensing Deals By Geography, 2007-2012 88
  • Figure 53: GBI Research Market Forecasting Model 96
Show More
Pricing
Get Notified
Email me when related reports are published